Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
INTROPIN vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dopamine is a direct agonist at dopamine (D1 and D2) and beta-1 adrenergic receptors, and at higher doses, alpha-1 adrenergic receptors. It also causes release of norepinephrine from sympathetic nerve terminals.
Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.
Hemodynamic support in cardiogenic shock,Hypotension not due to hypovolemia,Adjunct in cardiopulmonary resuscitation,Off-label: Bradycardia unresponsive to atropine
Treatment of herpes simplex virus (HSV) infections (genital herpes, herpes labialis, herpes simplex encephalitis),Treatment of varicella-zoster virus (VZV) infections (chickenpox, herpes zoster),Neonatal herpes simplex virus infection,Off-label: Prevention of HSV reactivation in immunocompromised patients, treatment of eczema herpeticum
2-20 mcg/kg/min continuous IV infusion, titrated to achieve desired hemodynamic response. Typical initial dose: 5 mcg/kg/min.
5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.
Approximately 2 minutes. Short half-life allows rapid titration by intravenous infusion; effects cease within 5-10 minutes of discontinuation.
Terminal elimination half-life in adults with normal renal function is 2.5-3.3 hours. In anuric patients, half-life extends to approximately 19.5 hours, necessitating dosage adjustment in renal impairment.
Metabolized in the liver, kidney, and plasma by monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT) to inactive metabolites.
Acyclovir is partially metabolized by aldehyde oxidase and alcohol dehydrogenase to 9-carboxymethoxymethylguanine and other minor metabolites. The majority (62-90%) is excreted unchanged in urine via glomerular filtration and tubular secretion.
Primarily renal: 80% as unchanged drug and 20% as inactive metabolites (normetanephrine, homovanillic acid). Biliary/fecal excretion is negligible (<2%).
Primarily renal excretion via glomerular filtration and tubular secretion; approximately 62-91% of an administered dose is recovered unchanged in urine. Fecal excretion is minimal (<2%).
25%, primarily to albumin.
9-33% bound to plasma proteins; binding is concentration-independent and predominantly to albumin.
0.2 L/kg (0.16-0.24 L/kg). Small Vd indicates limited extravascular distribution; compatible with rapid onset and offset.
Approximately 0.7 L/kg, indicating distribution into total body water. Penetrates well into tissues, including cerebrospinal fluid (CSF concentrations ~50% of plasma).
Oral: less than 5% due to extensive first-pass metabolism (MAO and COMT). Intramuscular: variable but limited due to peripheral vasoconstriction; not recommended.
Intravenous administration yields 100% bioavailability. Oral bioavailability is 15-30% (not applicable to IV formulation).
No specific GFR-based dose adjustment required; monitor for renal perfusion adequacy and adjust based on clinical response.
Cr Cl >50 m L/min: no adjustment; Cr Cl 25-50 m L/min: 5-10 mg/kg every 12 hours; Cr Cl 10-25 m L/min: 5-10 mg/kg every 24 hours; Cr Cl <10 m L/min: 2.5-5 mg/kg every 24 hours; hemodialysis: give dose after dialysis.
No specific Child-Pugh-based adjustment; use with caution in severe hepatic impairment due to altered metabolism.
No dose adjustment required for hepatic impairment; acyclovir is minimally metabolized by the liver.
0.5-20 mcg/kg/min continuous IV infusion; typical initial dose 2-5 mcg/kg/min, titrated to effect.
Neonates (0-3 months): 10 mg/kg IV every 8 hours for HSV; Infants and children (3 months-12 years): 10 mg/kg IV every 8 hours for HSV, 20 mg/kg IV every 8 hours for VZV; maximum dose 500 mg/m² per dose.
Start at lower end of dosing range (2-5 mcg/kg/min) due to increased sensitivity and comorbid conditions; titrate cautiously.
Elderly patients may have reduced renal function; adjust dose based on Cr Cl and monitor for neurotoxicity (e.g., confusion, hallucinations).
None
None.
Can cause ectopic heartbeats, tachycardia, angina, palpitations, vasoconstriction, and hypertension,May increase myocardial oxygen demand,Risk of tissue necrosis with extravasation,Use with caution in patients with occlusive vascular disease,Hypovolemia should be corrected before administration
Renal impairment: Dose adjustment required; monitor renal function.,Neurotoxicity: May cause agitation, hallucinations, confusion, seizures (especially in elderly or renally impaired).,Crystalluria: Risk increased with rapid infusion or dehydration; ensure adequate hydration.,Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP): Rare but serious, reported in immunocompromised patients.,Pregnancy: Use only if clearly needed (Category B).
Pheochromocytoma,Uncorrected tachyarrhythmias,Hypersensitivity to sulfites (if formulation contains sulfites),Ventricular fibrillation
Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation.,Neonates: Use of bacteriostatic water-containing preparations (e.g., benzyl alcohol) is contraindicated.
No significant food interactions. However, patients on INTROPIN may have underlying conditions requiring dietary modifications (e.g., low sodium for hypertension). Avoid tyramine-rich foods if also taking MAOIs, though not a direct interaction with dopamine itself.
No specific food interactions. Adequate fluid intake is recommended to prevent renal toxicity. Avoid concurrent use of nephrotoxic substances (e.g., certain NSAIDs, aminoglycosides) without medical supervision.
Pregnancy Category C. In first trimester, animal studies show fetal abnormalities (e.g., skeletal and visceral malformations) at high doses. Second and third trimesters: risk of reduced uteroplacental blood flow and fetal hypoxia due to vasoconstriction; may induce preterm labor.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; use only if clearly needed.
Excreted in breast milk in low concentrations; M/P ratio unknown. Potential for cardiovascular effects in infant; weigh benefits against risks.
Acyclovir excreted in breast milk at low levels; M/P ratio unknown. Typical infant dose ~0.6 mg/kg/day (2-3% of maternal IV dose). No adverse effects reported in breastfeeding infants. Compatible with breastfeeding; caution with high maternal doses.
No specific dose adjustment required; start at low doses and titrate to effect due to altered hemodynamics and increased plasma volume in pregnancy.
Increased renal clearance and volume of distribution in pregnancy may reduce acyclovir exposure. No dose adjustment routinely recommended; however, higher doses or more frequent dosing may be considered for severe infections. Monitor therapeutic response.
INTROPIN (dopamine) is a catecholamine with dose-dependent effects: low dose (1-5 mcg/kg/min) stimulates D1 receptors causing renal vasodilation; intermediate dose (5-10 mcg/kg/min) activates β1 receptors increasing cardiac contractility and heart rate; high dose (>10 mcg/kg/min) stimulates α1 receptors leading to vasoconstriction. Monitor for extravasation as it can cause tissue necrosis; treat with phentolamine infiltration. Taper infusion gradually to avoid hypotension. Contraindicated in pheochromocytoma and uncorrected tachyarrhythmias.
Acyclovir in sodium chloride 0.9% preservative-free is for IV administration only; do not administer IM or SC. Infuse over at least 1 hour to prevent renal tubular damage. Monitor renal function and adjust dose in renal impairment (Cr Cl <50 m L/min). Ensure adequate hydration (e.g., 500 m L IV fluids per gram acyclovir) to reduce risk of crystalluria. In obese patients, use ideal body weight for dosing. Phlebitis at infusion site is common; rotate sites.
This medication is given intravenously and requires continuous monitoring in a hospital setting.,Report any pain, burning, or swelling at the IV site immediately.,You may experience increased heart rate, chest pain, or shortness of breath; notify staff promptly.,Inform your healthcare provider if you have a history of irregular heartbeat, high blood pressure, or thyroid disease.,Do not stop or change the infusion rate; it is controlled by medical staff.
This medication is given intravenously (into a vein) to treat viral infections.,Drink plenty of fluids before and during treatment to prevent kidney problems.,Report any pain, redness, or swelling at the injection site, or any lower back pain.,Tell your healthcare provider if you have kidney disease or are taking other medications that can affect the kidneys.,This drug does not cure herpes infections but helps reduce symptoms and recurrence.
No interactions on record
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about INTROPIN vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, answered by our medical review team.
INTROPIN is a Catecholamine Vasopressor that works by Dopamine is a direct agonist at dopamine (D1 and D2) and beta-1 adrenergic receptors, and at higher doses, alpha-1 adrenergic receptors. It also causes release of norepinephrine from sympathetic nerve terminals.. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is a Electrolyte that works by Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between INTROPIN and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of INTROPIN is: 2-20 mcg/kg/min continuous IV infusion, titrated to achieve desired hemodynamic response. Typical initial dose: 5 mcg/kg/min.. The standard adult dose of ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is: 5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between INTROPIN and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. INTROPIN is classified as Category C. Pregnancy Category C. In first trimester, animal studies show fetal abnormalities (e.g., skeletal and visceral malformations) at high doses. Second and third trimesters: risk of re. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; us. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.